Make the016.com a preferred choice with Google by clicking here
Researchers are now testing treatments for several kinds of visual impairment. BRIAN MITCHELL / Getty Images
Hemant Khanna, University of Massachusetts Medical School
In recent months, even as our attention has been focused on the coronavirus outbreak, there have been a slew of scientific breakthroughs in treating diseases that cause blindness.
Researchers at U.S.-based Editas Medicine and Ireland-based Allergan have administered CRISPR for the first time to a person with a genetic disease. This landmark treatment uses the CRISPR approach to a specific mutation in a gene linked to childhood blindness. The mutation affects the functioning of the light-sensing compartment of the eye, called the retina, and leads to loss of the light-sensing cells.
According to the World Health Organization, at least 2.2 billion people in the world have some form of visual impairment. In the United States, approximately 200,000 people suffer from inherited forms of retinal disease for which there is no cure. But things have started to change for good. We can now see light at the end of the tunnel.
I am an ophthalmology and visual sciences researcher, and am particularly interested in these advances because my laboratory is focusing on designing new and improved gene therapy approaches to treat inherited forms of blindness.
Gene therapy involves inserting the correct copy of a gene into cells that have a mistake in the genetic sequence of that gene, recovering the normal function of the protein in the cell. The eye is an ideal organ for testing new therapeutic approaches, including CRISPR. That is because the eye is the most exposed part of our brain and thus is easily accessible.
The second reason is that retinal tissue in the eye is shielded from the body’s defense mechanism, which would otherwise consider the injected material used in gene therapy as foreign and mount a defensive attack response. Such a response would destroy the benefits associated with the treatment.
In recent years, breakthrough gene therapy studies paved the way to the first ever Food and Drug Administration-approved gene therapy drug, Luxturna TM, for a devastating childhood blindness disease, Leber congenital amaurosis Type 2.
This form of Leber congenital amaurosis is caused by mutations in a gene that codes for a protein called RPE65. The protein participates in chemical reactions that are needed to detect light. The mutations lessen or eliminate the function of RPE65, which leads to our inability to detect light – blindness.
The treatment method developed simultaneously by groups at University of Pennsylvania and at University College London and Moorefields Eye Hospital involved inserting a healthy copy of the mutated gene directly into the space between the retina and the retinal pigmented epithelium, the tissue located behind the retina where the chemical reactions takes place. This gene helped the retinal pigmented epithelium cell produce the missing protein that is dysfunctional in patients.
Although the treated eyes showed vision improvement, as measured by the patient’s ability to navigate an obstacle course at differing light levels, it is not a permanent fix. This is due to the lack of technologies that can fix the mutated genetic code in the DNA of the cells of the patient.
Lately, scientists have been developing a powerful new tool that is shifting biology and genetic engineering into the next phase. This breakthrough gene editing technology, which is called CRISPR, enables researchers to directly edit the genetic code of cells in the eye and correct the mutation causing the disease.
Children suffering from the disease Leber congenital amaurosis Type 10 endure progressive vision loss beginning as early as one year old. This specific form of Leber congenital amaurosis is caused by a change to the DNA that affects the ability of the gene – called CEP290 – to make the complete protein. The loss of the CEP290 protein affects the survival and function of our light-sensing cells, called photoreceptors.
One treatment strategy is to deliver the full form of the CEP290 gene using a virus as the delivery vehicle. But the CEP290 gene is too big to be cargo for viruses. So another approach was needed. One strategy was to fix the mutation by using CRISPR.
The scientists at Editas Medicine first showed safety and proof of the concept of the CRISPR strategy in cells extracted from patient skin biopsy and in nonhuman primate animals.
These studies led to the formulation of the first ever in human CRISPR gene therapeutic clinical trial. This Phase 1 and Phase 2 trial will eventually assess the safety and efficacy of the CRISPR therapy in 18 Leber congenital amaurosis Type 10 patients. The patients receive a dose of the therapy while under anesthesia when the retina surgeon uses a scope, needle and syringe to inject the CRISPR enzyme and nucleic acids into the back of the eye near the photoreceptors.
To make sure that the experiment is working and safe for the patients, the clinical trial has recruited people with late-stage disease and no hope of recovering their vision. The doctors are also injecting the CRISPR editing tools into only one eye.
An ongoing project in my laboratory focuses on designing a gene therapy approach for the same gene CEP290. Contrary to the CRISPR approach, which can target only a specific mutation at one time, my team is developing an approach that would work for all CEP290 mutations in Leber congenital amaurosis Type 10.
This approach involves using shorter yet functional forms of the CEP290 protein that can be delivered to the photoreceptors using the viruses approved for clinical use.
Gene therapy that involves CRISPR promises a permanent fix and a significantly reduced recovery period. A downside of the CRISPR approach is the possibility of an off-target effect in which another region of the cell’s DNA is edited, which could cause undesirable side effects, such as cancer. However, new and improved strategies have made such likelihood very low.
Although the CRISPR study is for a specific mutation in CEP290, I believe the use of CRISPR technology in the body to be exciting and a giant leap. I know this treatment is in an early phase, but it shows clear promise. In my mind, as well as the minds of many other scientists, CRISPR-mediated therapeutic innovation absolutely holds immense promise.
An infrared image of a man and a dog. German and Swiss researchers have shown that they can endow living mice with this type of vision. Joseph Giacomin
In another study just reported in the journal Science, German and Swiss scientists have developed a revolutionary technology, which enables mice and human retinas to detect infrared radiation. This ability could be useful for patients suffering from loss of photoreceptors and sight.
The researchers demonstrated this approach, inspired by the ability of snakes and bats to see heat, by endowing mice and postmortem human retinas with a protein that becomes active in response to heat. Infrared light is light emitted by warm objects that is beyond the visible spectrum.
The heat warms a specially engineered gold particle that the researchers introduced into the retina. This particle binds to the protein and helps it convert the heat signal into electrical signals that are then sent to the brain.
In the future, more research is needed to tweak the ability of the infrared sensitive proteins to different wave lengths of light that will also enhance the remaining vision.
This approach is still being tested in animals and in retinal tissue in the lab. But all approaches suggest that it might be possible to either restore, enhance or provide patients with forms of vision used by other species.
[Get our best science, health and technology stories. Sign up for The Conversation’s science newsletter
Hemant Khanna, Associate Professor of Ophthalmology, University of Massachusetts Medical School
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Make the016.com a preferred choice with Google by clicking here
In The News
>WEATHER: Mark Rosenthal's 7-day forecast (:20). High of 75 today in Worcester
>TOP OF THE NEWS
-Accused Shrewsbury shooter saw machete assault charges dropped last month
-Related: Fundraiser, vigil for slain Shrewsbury man to be held October 11th
-Worcester legislators accuse state of wrongdoing regarding $30 million+ Holden sewer lawsuit
-New Worcester Superintendent Brian Allen talks 1 on 1 about leading the district where he grew up
-Worcester board to review proposal for 10 housing units on Heywood Street
-Radio Worcester (11:51): WooSox president addresses homelessness near Polar Park
-Benefit Bake fundraiser at American Flatbread in Worcester on September 2nd
-How Journalism Works series kicks off September 6th at Worcester Public Library
-Smiles Four Balloons: A family’s passion turned profession
-The Worcester Guardian's Week in Review
-Powerball jackpot jumps to $1.1 billion after no winning tickets Saturday
>POLITICS: Meet the candidates: Jermoh Kamara on health, schools, community
-The016.com announces political ad packages
-WCCA-TV's Primary Candidate Forum (41:14)
>DINING OUT: Ladd’s Restaurant & Lounge in Rutland celebrates 25 years
-ICYMI: Worcester police ask for help finding missing 14-year-old
-Shrewsbury shooting victim ID'd as Kevin Doherty, 56; suspect arraigned
-Related: New details revealed in deadly shooting of Shrewsbury dad (3:03)
-Related: Machete attack victim says suspect should have been in jail (2:46). Article
-Earlier: Shrewsbury father shot to death after walking 6-year-old child to school (2:58). Article
-Firefighters battle blaze at scrap metal site in Worcester
-See the rest of the day's Worcester news
>HOLDEN (brought to you by Lamoureux Ford): Scenes from Holden Days
-America's newest game show, filmed at Lamoureux Ford (1:40)
-Holden recreation fields formally opened
>THE BURBS (brought to you by North End Motor Sales): Traffic stop in Auburn leads to pond rescue, gun bust
-Millbury declines to say if it fired firefighter jailed for child rape
-New signage at Shrewsbury soccer fields? It’s this Boy Scout’s service project
-More than 40 people become U.S. citizens in Tower Hill ceremony
-Oxford man charged with O.U.I. after allegedly driving 51 in 35 zone with 2 loaded guns in truck
-Some food choices at Olde Home Day
-Rutland hires help in administrator search
-Sutton High School student among recipients of local bank scholarships
>BARS & BANDS: The Mayor's Live Music List for Sunday
-Jazzed Up Trio at Pinecroft Dairy 5 p.m. Sunday
>SHOWTIME: Things to Do: Chainsmokers at Breakaway Festival, KC and the Sunshine Band and more ...
-Nine Inch Nails hits home hard with fans at TD Garden
-Lady Gaga at MTV Video Music Awards: Here's everything to know
-Ariana Falk new executive director as Worcester Chamber Music Society enters 20th season
>OPINION: Laurel: Backyard physics at play in Worcester
-Shaun Connolly: Back to school tips & tricks
>OBITUARIES: Tribute to local man who was a truck driver for over 40 years
>SPORTS: Elijah Ponder might be best-kept secret of Patriots’ rookie class
-Patriots better than past years, but depth issues remain (10:15)
-Holy Cross football edged by Northern Illinois, 19-17
-Christian Ross remains model of consistency, compassion and hard work for Holy Cross football
-Boston College routs Fordham, 66-10
-Red Sox lose to Pirates, 10-3
-WooSox lose to Durham, 7-2
-Shrewsbury's Altomare, Westborough's Pano enjoy playing with LPGA in Norton
>CARS: Ford recalls more than 355,000 trucks over instrument panel issue
>NATIONAL: Social Security whistleblower resigns
-ChatGPT gave instructions on how to bomb arenas, make anthrax and illegal drugs, alarmed researchers reveal
-Bones found during manhunt for fugitive dad over murders of his 3 daughters
>TRAGIC: Pregnant teen shot in head during road rage
>NEW ENGLAND: Karen Read speaks out, hints at possible lawsuit in interview (1:50)
-Business owner says mom in N.H. murder-suicide stole over $600,000 from company (1:59)
>COLLEGES: Clark's Elyse Semerdjian receives prestigious book award
-What Mass. schools are saying about immigration enforcement as students return (2:49). Article
>TRAVEL (brought to you by Fuller RV & Rental): Planning a foliage tour? Reader's Digest says Berkshire town is stunning
>BUSINESS: Spirit Airlines files for bankruptcy again
-C.C.C. reaches $43,000 settlement with whistleblower, adding to $1.1 million spent on legal and employment issues
>SHOPPING: Back to school shopping deals at Goodwill, secondhand shops
>HOMES: HGTV named the best garden in Mass. It's not the one you're thinking of
>HEALTH: TikTok's viral "6-6-6" walking routine burns fat without grueling workouts
-Medicare program to use A.I. for pre-approval of medical procedures
>FOOD: Elizabeth Chirico: Best coffee spots with kids in tow
>TV/STREAMING: Trailer for Season 13 of "The Great British Baking Show" (1:50)
>MOVIES: Drive-in movie theaters saw a surge during the pandemic. Are they sticking around?
>CELEBRITY: Kevin Costner "casually" seeing billionaire’s ex-wife after divorce
-Charlize Theron, 49, raves about having sex with 26-year-old
>ANIMALS: "Very aggressive" shelter dog turns into the sweetest girl (2:05)
>HISTORY: Then & Now: Sever Street School, 9 Sever St., Worcester
>GOOD NEWS: 9-year-old boy opens a "compliment stand" to boost people's self esteem (2:20)
-Meanwhile, in Idaho, watch man take 96 wet sponge hits to the face in a minute
Latest obituaries | | Saturday's Highlights | | Today's horoscope | | Local Sports
Quick Links: Personalize your news | | Browse members | | Advertise | | Blogs | | Invite friends | | Videos
Animals | | Boston Sports | | Business | | Cars | | Celebrity | | Colleges | | Commute & Travel | | Crime | | Faith | | Food | | Good News | | Health | | Help Wanted | History | | Homes | | Local Sports | | Lottery | | Movies | | National | | New England | | Politics | | Shopping & Deals | | SHOWTIME! | | TV & Streaming | | Weather